SCHEMBL18613698

SCHEMBL18613698

Cc1cc(C)c(C(C)(C)CC=O)c(OC(=O)CCC(=O)Oc2cc(C)cc(C)c2C(C)(C)CC=O)c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.36
HSD17B10 Q99714 2/20 0.36
ALDH1A1 P00352 3/20 0.33
TSHR P16473 3/20 0.33
HPGD P15428 2/20 0.33
LMNA P02545 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP2C9 P11712 2/20 0.32
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
FABP4 P15090 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18613700 0.96 TSHR (0.36) MAPTHSD17B10ALDH1A1TSHRHPGD
SCHEMBL28535446 0.95 ALDH1A1 (0.35) MAPTHSD17B10ALDH1A1TSHRHPGD
SCHEMBL24878406 0.95 MAPT (0.33) MAPTHSD17B10ALDH1A1TSHRHPGD
SCHEMBL19608800 0.93 ALOX15 (0.36) MAPTHSD17B10ALDH1A1TSHRHPGD
SCHEMBL5605689 0.91 ALDH1A1 (0.35) MAPTHSD17B10ALDH1A1TSHRHPGD
SCHEMBL25653711 0.89 TOP2A (0.39) LMNAALOX15KMT2ASMN1; SMN2
SCHEMBL15283358 0.87 ALDH1A1 (0.37) MAPTHSD17B10ALDH1A1HPGDLMNA
SCHEMBL26264818 0.87 AR (0.33)
SCHEMBL18114100 0.86 ELANE (0.40) MAPTALDH1A1LMNANPSR1CYP2C9
SCHEMBL17464403 0.85 ALDH1A1 (0.52) MAPTHSD17B10ALDH1A1TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118063537-A Prodrugs of directed lymphatics 莫纳什大学 2024-05-24 CN disclosed
CN-108137482-B Prodrugs of directed lymphatics 莫纳什大学 2024-03-15 CN disclosed
US-20240050573-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2024-02-15 US disclosed
US-11738087-B2 Lymph directing prodrugs MONASH UNIVERSITY (AU) 2023-08-29 US disclosed
CN-114031658-A Lymphatic prodrugs 莫纳什大学 2022-02-11 CN disclosed
US-20180243425-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2018-08-30 US disclosed
EP-3347340-A1 LYMPH DIRECTING PRODRUGS Monash University (AU) 2018-07-18 EP disclosed
WO-2017041139-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2017-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240050573-A1 LYMPH DIRECTING PRODRUGS LTA, ABCB11, LYN MAPT 2633/4885HSD17B10 1871/4885ALDH1A1 1056/4885
US-20180243425-A1 LYMPH DIRECTING PRODRUGS MLNR, ABCB11, MLN MAPT 1774/4885HSD17B10 2244/4885ALDH1A1 1385/4885
US-11738087-B2 Lymph directing prodrugs MLNR, ABCB11, MLN MAPT 1774/4885HSD17B10 2244/4885ALDH1A1 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.